NAGE250516P7500
- 0.20
- -0.35-63.64%
Niagen Bioscience Newsroom
Earnings Preview: NAGE to Report Financial Results Post-market on May 07
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
Express News | Niagen Bioscience Welcomes DR. Pinchas Cohen to Scientific Advisory Board
Press Release: Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
Roth MKM Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $8
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Niagen Says Its Operations Remain Resilient Amid Recent Tariff Developments
Niagen Bioscience (NAGE) Gets a Buy From Roth MKM
Investors Appear Satisfied With Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Prospects As Shares Rocket 29%
H.C. Wainwright Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $11
Express News | HC Wainwright & Co. Reiterates Buy on Niagen Bioscience, Maintains $11 Price Target
Niagen Bioscience Analyst Ratings
Calculating The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)
Niagen Bioscience Broadens NAD+ Precursor IP Portfolio With New Patent
Niagen Bioscience Gets US Composition of Matter Patent for Nicotinamide Riboside Salt Forms
Niagen Bioscience Secures US Patent For Composition Of Matter For Nicotinamide Riboside Salt Forms
News On ChromaDex Corp. (CDXC) Now Under NAGE
H.C. Wainwright Maintains ChromaDex(CDXC.US) With Buy Rating, Maintains Target Price $11
U.S. Egg Prices Halve Since January Peak, White House Notes
Chromadex's Strategic Rebranding and Promising Clinical Developments Justify Buy Rating